Lipoic acid choline ester

Drug Profile

Lipoic acid choline ester

Alternative Names: EV-06; Thioctic acid choline ester; UNR 844

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encore Vision
  • Developer Novartis
  • Class Carboxylic acids; Coenzymes; Eye disorder therapies; Fatty acids; Thiophenes
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Presbyopia

Most Recent Events

  • 03 Apr 2017 Novartis intends to submit NDA to the US FDA for Presbyopia in 2021
  • 20 Jan 2017 Encore Vision has been acquired and merged into Novartis
  • 05 May 2016 Efficacy and adverse event data from a phase I/II trial in Presbyopia released by Encore Vision
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top